Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (10): 1012-1017.DOI: 10.3969/j.issn.1673-8640.2026.10.012
Previous Articles Next Articles
WEI Tianli, XIAO Nan(
), ZHU Tianyang, DUAN Ning, ZHAO Xiuying
Received:2024-11-08
Revised:2025-11-19
Online:2026-10-30
Published:2026-10-20
CLC Number:
WEI Tianli, XIAO Nan, ZHU Tianyang, DUAN Ning, ZHAO Xiuying. Identification and antimicrobial susceptibility analysis of Actinomycetes causing cutaneous and soft tissue actinomycosis[J]. Laboratory Medicine, 2026, 41(10): 1012-1017.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.10.012
| 抗菌药物 | 雷丁放线菌 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 第1株 | 第2株 | 第3株 | 第4株 | 第5株 | 第6株 | 第7株 | 第8株 | 第9株 | 第10株 | 第11株 | ||||
| 青霉素 | 0.024 | 0.012 | 0.032 | 0.064 | 0.250 | 0.064 | 0.064 | 0.016 | 0.064 | 0.024 | 0.024 | |||
| 阿莫西林-克拉维酸 | 0.016 | <0.008 | 0.016 | 0.032 | 0.032 | 0.032 | <0.008 | <0.008 | 0.032 | <0.008 | <0.008 | |||
| 头孢曲松 | 0.064 | 0.032 | 0.125 | 0.190 | 0.750 | 0.190 | 0.064 | 0.032 | 0.190 | 0.125 | 0.032 | |||
| 亚胺培南 | 0.016 | 0.008 | 0.016 | 0.024 | 0.032 | 0.024 | 0.016 | 0.024 | 0.032 | 0.016 | 0.012 | |||
| 美罗培南 | 0.125 | 0.064 | 0.125 | 0.190 | 0.250 | 0.125 | 0.125 | 0.125 | 0.380 | 0.190 | 0.094 | |||
| 利奈唑胺 | 0.125 | 0.250 | 0.250 | 0.125 | 0.250 | 0.250 | 0.125 | 0.250 | 0.250 | 0.250 | 0.250 | |||
| 万古霉素 | 0.250 | 0.250 | 0.250 | 0.380 | 0.500 | 0.500 | 0.380 | 0.500 | 0.380 | 0.380 | 0.380 | |||
| 红霉素 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | |||
| 克拉霉素 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | |||
| 庆大霉素 | 8 | 16 | 2 | 4 | 8 | 8 | 4 | 8 | 8 | 4 | 4 | |||
| 妥布霉素 | 16 | 64 | 8 | 32 | 64 | 64 | 16 | 64 | 64 | 32 | 32 | |||
| 环丙沙星 | >32 | 0.125 | >32 | >32 | 0.064 | 0.250 | >32 | >32 | 0.125 | >32 | >32 | |||
| 左氧氟沙星 | >32 | 0.250 | >32 | >32 | 0.125 | 0.250 | >32 | >32 | 0.250 | >32 | >32 | |||
| 米诺环素 | 0.125 | 1 | 0.250 | 0.125 | 0.125 | 0.250 | 0.250 | 0.125 | 0.125 | 0.125 | 0.250 | |||
| 多西环素 | 0.250 | 8 | 0.500 | 0.125 | 0.500 | 0.250 | 1 | 0.125 | 0.250 | 0.250 | 0.250 | |||
| 克林霉素 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | |||
| 复方磺胺甲噁唑 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | |||
| 抗菌药物 | 欧洲放线菌 | 苏黎世放线菌 | 诺伊放线菌 | |||||||||||
| 第1株 | 第2株 | 第3株 | 第4株 | 第5株 | 第6株 | 第1株 | 第2株 | 第3株 | 第4株 | 第1株 | 第2株 | 第3株 | ||
| 青霉素 | 0.048 | 0.024 | 0.380 | 0.500 | 0.380 | 0.032 | 0.125 | 0.008 | 0.125 | 0.125 | 0.016 | 0.008 | 0.016 | |
| 阿莫西林/克拉维酸 | 0.032 | <0.008 | 0.125 | <0.008 | 0.125 | <0.008 | 0.125 | <0.008 | 0.125 | 0.064 | <0.008 | <0.008 | <0.008 | |
| 头孢曲松 | 0.190 | 0.032 | 0.500 | 1.500 | 1.500 | 0.190 | 0.190 | 0.016 | 0.125 | 0.125 | 0.016 | 0.032 | 0.048 | |
| 亚胺培南 | 0.125 | 0.032 | 0.190 | 0.380 | 0.500 | 0.064 | 0.064 | 0.012 | 0.094 | 0.048 | 0.008 | 0.008 | 0.016 | |
| 美罗培南 | 0.125 | 0.024 | 0.190 | 0.380 | 0.250 | 0.048 | 0.190 | 0.024 | 0.190 | 0.125 | 0.008 | 0.008 | 0.016 | |
| 利奈唑胺 | 0.250 | 0.250 | 0.125 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | |
| 万古霉素 | 0.380 | 0.380 | 0.380 | 0.380 | 0.380 | 0.250 | 0.380 | 0.380 | 0.380 | 0.500 | 0.380 | 0.380 | 0.380 | |
| 红霉素 | 0.125 | >256 | >256 | >256 | >256 | <0.064 | 2 | >256 | >256 | 0.064 | 0.064 | 16 | <0.064 | |
| 克拉霉素 | 0.016 | 16 | >32 | >32 | >32 | 0.016 | 0.250 | >32 | 8 | 0.016 | 0.016 | 0.500 | 0.008 | |
| 庆大霉素 | 2 | 2 | >256 | 4 | >256 | 4 | 2 | 2 | 4 | 1 | 4 | 4 | 2 | |
| 妥布霉素 | 4 | 4 | 64 | 4 | >256 | 4 | 4 | 8 | 8 | 4 | 8 | 4 | 4 | |
| 环丙沙星 | >32 | 0.500 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | 2 | 2 | 1 | |
| 左氧氟沙星 | >32 | 1 | >32 | >32 | >32 | >32 | >32 | 4 | 8 | >32 | 2 | 2 | 1 | |
| 米诺环素 | 2 | 0.125 | 0.064 | 0.064 | 1 | 2 | 2 | 0.064 | 0.064 | 0.064 | 0.125 | 0.064 | 0.064 | |
| 多西环素 | 4 | 0.125 | 0.125 | 0.250 | 8 | 8 | 4 | 0.250 | 0.125 | 0.125 | 0.500 | 0.250 | 0.250 | |
| 克林霉素 | 0.250 | >256 | >256 | >256 | >256 | 0.125 | <0.064 | >256 | >256 | <0.064 | 0.125 | >256 | <0.064 | |
| 复方磺胺甲噁唑 | >32 | >32 | >32 | >32 | >32 | >32 | 2 | 0.500 | 0.125 | <0.008 | 0.500 | 0.032 | 0.032 | |
| 抗菌药物 | 雷丁放线菌 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 第1株 | 第2株 | 第3株 | 第4株 | 第5株 | 第6株 | 第7株 | 第8株 | 第9株 | 第10株 | 第11株 | ||||
| 青霉素 | 0.024 | 0.012 | 0.032 | 0.064 | 0.250 | 0.064 | 0.064 | 0.016 | 0.064 | 0.024 | 0.024 | |||
| 阿莫西林-克拉维酸 | 0.016 | <0.008 | 0.016 | 0.032 | 0.032 | 0.032 | <0.008 | <0.008 | 0.032 | <0.008 | <0.008 | |||
| 头孢曲松 | 0.064 | 0.032 | 0.125 | 0.190 | 0.750 | 0.190 | 0.064 | 0.032 | 0.190 | 0.125 | 0.032 | |||
| 亚胺培南 | 0.016 | 0.008 | 0.016 | 0.024 | 0.032 | 0.024 | 0.016 | 0.024 | 0.032 | 0.016 | 0.012 | |||
| 美罗培南 | 0.125 | 0.064 | 0.125 | 0.190 | 0.250 | 0.125 | 0.125 | 0.125 | 0.380 | 0.190 | 0.094 | |||
| 利奈唑胺 | 0.125 | 0.250 | 0.250 | 0.125 | 0.250 | 0.250 | 0.125 | 0.250 | 0.250 | 0.250 | 0.250 | |||
| 万古霉素 | 0.250 | 0.250 | 0.250 | 0.380 | 0.500 | 0.500 | 0.380 | 0.500 | 0.380 | 0.380 | 0.380 | |||
| 红霉素 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | |||
| 克拉霉素 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | |||
| 庆大霉素 | 8 | 16 | 2 | 4 | 8 | 8 | 4 | 8 | 8 | 4 | 4 | |||
| 妥布霉素 | 16 | 64 | 8 | 32 | 64 | 64 | 16 | 64 | 64 | 32 | 32 | |||
| 环丙沙星 | >32 | 0.125 | >32 | >32 | 0.064 | 0.250 | >32 | >32 | 0.125 | >32 | >32 | |||
| 左氧氟沙星 | >32 | 0.250 | >32 | >32 | 0.125 | 0.250 | >32 | >32 | 0.250 | >32 | >32 | |||
| 米诺环素 | 0.125 | 1 | 0.250 | 0.125 | 0.125 | 0.250 | 0.250 | 0.125 | 0.125 | 0.125 | 0.250 | |||
| 多西环素 | 0.250 | 8 | 0.500 | 0.125 | 0.500 | 0.250 | 1 | 0.125 | 0.250 | 0.250 | 0.250 | |||
| 克林霉素 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | >256 | |||
| 复方磺胺甲噁唑 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | |||
| 抗菌药物 | 欧洲放线菌 | 苏黎世放线菌 | 诺伊放线菌 | |||||||||||
| 第1株 | 第2株 | 第3株 | 第4株 | 第5株 | 第6株 | 第1株 | 第2株 | 第3株 | 第4株 | 第1株 | 第2株 | 第3株 | ||
| 青霉素 | 0.048 | 0.024 | 0.380 | 0.500 | 0.380 | 0.032 | 0.125 | 0.008 | 0.125 | 0.125 | 0.016 | 0.008 | 0.016 | |
| 阿莫西林/克拉维酸 | 0.032 | <0.008 | 0.125 | <0.008 | 0.125 | <0.008 | 0.125 | <0.008 | 0.125 | 0.064 | <0.008 | <0.008 | <0.008 | |
| 头孢曲松 | 0.190 | 0.032 | 0.500 | 1.500 | 1.500 | 0.190 | 0.190 | 0.016 | 0.125 | 0.125 | 0.016 | 0.032 | 0.048 | |
| 亚胺培南 | 0.125 | 0.032 | 0.190 | 0.380 | 0.500 | 0.064 | 0.064 | 0.012 | 0.094 | 0.048 | 0.008 | 0.008 | 0.016 | |
| 美罗培南 | 0.125 | 0.024 | 0.190 | 0.380 | 0.250 | 0.048 | 0.190 | 0.024 | 0.190 | 0.125 | 0.008 | 0.008 | 0.016 | |
| 利奈唑胺 | 0.250 | 0.250 | 0.125 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | 0.250 | |
| 万古霉素 | 0.380 | 0.380 | 0.380 | 0.380 | 0.380 | 0.250 | 0.380 | 0.380 | 0.380 | 0.500 | 0.380 | 0.380 | 0.380 | |
| 红霉素 | 0.125 | >256 | >256 | >256 | >256 | <0.064 | 2 | >256 | >256 | 0.064 | 0.064 | 16 | <0.064 | |
| 克拉霉素 | 0.016 | 16 | >32 | >32 | >32 | 0.016 | 0.250 | >32 | 8 | 0.016 | 0.016 | 0.500 | 0.008 | |
| 庆大霉素 | 2 | 2 | >256 | 4 | >256 | 4 | 2 | 2 | 4 | 1 | 4 | 4 | 2 | |
| 妥布霉素 | 4 | 4 | 64 | 4 | >256 | 4 | 4 | 8 | 8 | 4 | 8 | 4 | 4 | |
| 环丙沙星 | >32 | 0.500 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | 2 | 2 | 1 | |
| 左氧氟沙星 | >32 | 1 | >32 | >32 | >32 | >32 | >32 | 4 | 8 | >32 | 2 | 2 | 1 | |
| 米诺环素 | 2 | 0.125 | 0.064 | 0.064 | 1 | 2 | 2 | 0.064 | 0.064 | 0.064 | 0.125 | 0.064 | 0.064 | |
| 多西环素 | 4 | 0.125 | 0.125 | 0.250 | 8 | 8 | 4 | 0.250 | 0.125 | 0.125 | 0.500 | 0.250 | 0.250 | |
| 克林霉素 | 0.250 | >256 | >256 | >256 | >256 | 0.125 | <0.064 | >256 | >256 | <0.064 | 0.125 | >256 | <0.064 | |
| 复方磺胺甲噁唑 | >32 | >32 | >32 | >32 | >32 | >32 | 2 | 0.500 | 0.125 | <0.008 | 0.500 | 0.032 | 0.032 | |
| [1] | Wong V K, Turmezei T D, Weston V C. Actinomycosis[J]. BMJ, 2011,343:d6099. |
| [2] |
Barberis C, Budia M, Palombarani S, et al. Antimicrobial susceptibility of clinical isolates of Actinomyces and related genera reveals an unusual clindamycin resistance among Actinomyces urogenitalis strains[J]. J Glob Antimicrob Resist, 2017, 8:115-120.
DOI PMID |
| [3] |
Steininger C, Willinger B. Resistance patterns in clinical isolates of pathogenic Actinomyces species[J]. J Antimicrob Chemother, 2016, 71(2):422-427.
DOI PMID |
| [4] | Valour F, Sénéchal A, Dupieux C, et al. Actinomycosis:etiology,clinical features,diagnosis,treatment,and management[J]. Infect Drug Resist, 2014, 7:183-197. |
| [5] |
Demirhan S, Orner E, Szymczak W, et al. Skin and soft tissue actinomycosis in children and adolescents[J]. Pediatr Infect Dis J, 2024, 43(8):743-747.
DOI PMID |
| [6] |
Boyanova L, Kolarov R, Mateva L, et al. Actinomycosis:a frequently forgotten disease[J]. Future Microbiol, 2015, 10(4):613-628.
DOI URL |
| [7] |
Xu Y Y, Zhang J, Lu A L, et al. Clinical features of actinomycosis:a 20-year experience of a single institute in Southern China[J]. J Mycol Med, 2021, 31(3):101169.
DOI URL |
| [8] |
Kapoor A K, Naqvi S, Padival S. A first case of prosthetic joint infection with Actinomyces radingae[J]. Anaerobe, 2023, 80:102662.
DOI URL |
| [9] | Olson J M, Vary J C Jr. Primary cutaneous Actinomyces neuii infection of the breast successfully treated with doxycycline[J]. Cutis, 2013, 92(6):E3-E4. |
| [10] |
Attar K H, Waghorn D, Lyons M, et al. Rare species of actinomyces as causative pathogens in breast abscess[J]. Breast J, 2007, 13(5):501-505.
PMID |
| [11] |
Anthony N, Douthit N T, Foster A. Actinomyces europaeus as an emerging cause of necrotizing fasciitis[J]. IDCases, 2023, 31:e01712.
DOI URL |
| [12] |
Chudácková E, Geigerová L, Hrabák J, et al. Seven isolates of Actinomyces turicensis from patients with surgical infections of the anogenital area in a Czech hospital[J]. J Clin Microbiol, 2010, 48(7):2660-2661.
DOI PMID |
| [13] |
Könönen E, Wade W G. Actinomyces and related organisms in human infections[J]. Clin Microbiol Rev, 2015, 28(2):419-442.
DOI URL |
| [14] |
Kövér Z, Johansen Nordskag V, Bán Á, et al. The role of Actinomyces spp. and related organisms in cervicofacial infections:pathomechanism,diagnosis and therapeutic aspects[J]. Anaerobe, 2023, 82:102767.
DOI URL |
| [15] |
Cobo F, Pérez-carrasco V, Martín-hita L, et al. Comparative evaluation of MALDI-TOF MS and 16S rRNA gene sequencing for the identification of clinically relevant anaerobic bacteria:critical evaluation of discrepant results[J]. Anaerobe, 2023, 82:102754.
DOI URL |
| [16] |
Bonifaz A, Tirado-sánchez A, Calderón L, et al. Treatment of cutaneous actinomycosis with amoxicillin/clavulanic acid[J]. J Dermatolog Treat, 2017, 28(1):59-64.
DOI PMID |
| [17] |
Kim S R, Jung L Y, Oh I J, et al. Pulmonary actinomycosis during the first decade of 21st century:cases of 94 patients[J]. BMC Infect Dis, 2013, 13:216.
DOI PMID |
| [18] |
Wolff A, Rodloff A C, Vielkind P, et al. Antimicrobial susceptibility of clinical oral isolates of Actinomyces spp[J]. Microorganisms, 2022, 10(1):125.
DOI URL |
| [19] |
Smith A J, Hall V, Thakker B, et al. Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agents[J]. J Antimicrob Chemother, 2005, 56(2):407-409.
DOI URL |
| [20] | Gajdács M, Urbán E. The pathogenic role of Actinomyces spp. and related organisms in genitourinary infections:discoveries in the new,modern diagnostic era[J]. Antibiotics(Basel), 2020, 9 (8):524. |
| [21] | Gajdács M, Urbán E, Terhes G. Microbiological and clinical aspects of cervicofacial Actinomyces infections:an overview[J]. Dent J(Basel), 2019, 7(3):85. |
| [22] |
Lozano C, Aspiroz C, Sáenz Y, et al. Genetic environment and location of the lnu(A)and lnu(B)genes in methicillin-resistant Staphylococcus aureus and other Staphylococci of animal and human origin[J]. J Antimicrob Chemother, 2012, 67(12):2804-2808.
DOI URL |
| [23] |
Hays C, Lienhard R, Auzou M, et al. Erm(X)-mediated resistance to macrolides,lincosamides and streptogramins in Actinobaculum schaalii[J]. J Antimicrob Chemother, 2014, 69(8):2056-2060.
DOI URL |
| [1] | KANG Beipei, ZHENG Tian, FU Xiaorui, YANG Peihong, HE Wenfang, ZHOU Shan, ZHOU Ke. Role of MALDI-TOF MS in the homology analysis of vancomycin-resistant Enterococcus faecium [J]. Laboratory Medicine, 2026, 41(9): 891-895. |
| [2] | YANG Peihong, ZHOU Shan, KANG Beipei, YANG Yuqi, LIU Hao, ZHOU Ke. Distribution and in vitro drug susceptibility test of Nocardia in Xi'an [J]. Laboratory Medicine, 2026, 41(7): 631-636. |
| [3] | WENG Wenhao. Iteration of laboratory diagnostic technologies for colorectal cancer:from early screening optimization to precise monitoring of MRD [J]. Laboratory Medicine, 2026, 41(4): 309-317. |
| [4] | FAN Yongbing, SHI Mengge, QU Linlin. Research progress on the application of MALDI-TOF MS in the diagnosis and monitoring of colorectal cancer [J]. Laboratory Medicine, 2026, 41(4): 318-325. |
| [5] | LÜ Na, LI Fangning, BAI Qi, ZHAO Mingliang, LI Youran, CAO Yan, ZHAI Yanhong, LI Na, CAO Zheng. Correlation between short stature,tic disorders and mineral elements in whole blood [J]. Laboratory Medicine, 2025, 40(8): 742-750. |
| [6] | LIN Jing, LI Quanle, YU Ting, WANG Huimin, SHEN Min, TU Minmin, CHEN Chuanding, PAN Jingjue, MA Jingxia. Establishment and performance evaluation of candidate reference measurement procedures for serum oxcarbazepine and 10-hydroxy carbamazepine [J]. Laboratory Medicine, 2025, 40(11): 1082-1090. |
| [7] | FAN Xiaoyu, LI Qing, TU Jiaxin, JIN Zhonggan, YU Keying, SUN Hewei, LUO Xialin, JU Yi. Application of inductively coupled plasma mass spectrometry in clinical laboratory medicine [J]. Laboratory Medicine, 2025, 40(11): 1126-1131. |
| [8] | FANG Huiling, JU Yi, OU Yuanzhu, ZHU Yuqing, LI Qing, JIN Zhonggan, ZHAO Xiaojun, FAN Xiaoyu, YU Keying. Current status of liquid chromatography-tandem mass spectrometry in clinical laboratories in Shanghai [J]. Laboratory Medicine, 2024, 39(9): 853-858. |
| [9] | LIN Jing, PAN Qingqing, SHEN Min, XIE Yangmin, JIN Zhonggan, PAN Jingjue, LIU Jiajuan. Establishment and performance evaluation of candidate reference measurement procedures for serum voriconazole [J]. Laboratory Medicine, 2024, 39(7): 661-667. |
| [10] | WU Xinzhe, MAO Haifeng, YANG Jin, ZUO Chunlei, JIN Danting. Clinical application of MALDI-TOF direct droplet culture method in rapid determination of CRKP [J]. Laboratory Medicine, 2024, 39(6): 587-591. |
| [11] | DUAN Xuehan, WU Hua. Application of MALDI-TOF MS technology in clinical microbiological examination [J]. Laboratory Medicine, 2024, 39(4): 410-414. |
| [12] | LI Anqi, ZHANG Shuya, HE Shanna, CHEN Qiaoqiao, LÜ Qi, LÜ Wanfei, LI Chunxian, WANG Weihua, ZHENG Lin. Rapid bacterial identification and drug susceptibility test of blood culture-positive samples [J]. Laboratory Medicine, 2024, 39(3): 243-248. |
| [13] | LIU Ruiguang, GUO Jian. Hospital and external environmental fungal screening and drug susceptibility analysis [J]. Laboratory Medicine, 2024, 39(12): 1150-1156. |
| [14] | LI Xijiu, ZHOU Jianwei, ZHANG Qin, LONG Yunlin, WU Yingsong. Establishment and performance evaluation of UPLC-MS/MS for 6 markers in dried blood spots [J]. Laboratory Medicine, 2023, 38(5): 446-453. |
| [15] | XU Weixin, CHEN Qing, DU Wenyong, GAO Yan. Plasma metabolic markers in patients with insomnia disorder [J]. Laboratory Medicine, 2023, 38(5): 454-459. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||